Intensive care drug therapy and its potential adverse effects on blood pressure and heart rate in critically ill children.

"Declarations Conflict of interestA Bertsche reports grants from UCB Pharma GmbH and honoraria for speaking engagements from Biogen GmbH, Desitin Arzneimittel GmbH, Eisai GmbH, GW Pharma GmbH, Neuraxpharm GmbH, Shire/Takeda GmbH, UCB Pharma GmbH, and ViroPharma GmbH. The other authors declare they have no financial or non-financial benefits received or will receive from any party related directly or indirectly to the subject of this article. Ethical approvalThe study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Medical Faculty, Leipzig University, Germany (127/19-ek). As this was a retrospective study and data were collected from patient records without any influence on patients’ treatment, the ethics committee waived informed consent. Conflict of interest A Bertsche reports grants from UCB Pharma GmbH and honoraria for speaking engagements from Biogen GmbH, Desitin Arzneimittel GmbH, Eisai GmbH, GW Pharma GmbH, Neuraxpharm GmbH, Shire/Takeda GmbH, UCB Pharma GmbH, and ViroPharma GmbH. The other authors declare they have no financial or non-financial benefits received or will receive from any party related directly or indirectly to the subject of this article."

"Funding Open Access funding enabled and organized by Projekt DEAL. No funding was received for conducting this study."